Biotech Values

[DewDiligence]

BMY +4% on 1Q17 results/raised 2017 guidance:

https://investors.bms.com/iframes/press-releases/press-release-details/2017/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results/default.aspx

Bristol-Myers Squibb is increasing its 2017 GAAP EPS guidance range from $2.47-$2.67 to $2.72-$2.87, and is increasing its non-GAAP EPS guidance range from $2.70-$2.90 to $2.85-$3.00. Both GAAP and non-GAAP guidance assume current exchange rates.

I.e., both the GAAP and non-GAAP EPS ranges were raised and narrowed: the lower bound was raised $0.20 for GAAP and $0.15 for non-GAAP, while the upper bound was raised $0.15 for GAAP and $0.10 for non-GAAP.